EVOLUS, INC. Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
EVOLUS, INC. (EOLS) reported Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents of -$180.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Change in Cash
us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-05
- EVOLUS, INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2026-03-31 was -$10.00K, a 115.15% decline year-over-year.
- EVOLUS, INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2025-03-31 was $66.00K.
- EVOLUS, INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2024-03-31 was -$130.00K.
- EVOLUS, INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2023-03-31 was -$79.00K.
- EVOLUS, INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2025 was $254.00K.
- EVOLUS, INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2024 was -$478.00K.
- EVOLUS, INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2023 was -$90.00K.
- EVOLUS, INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2022 was -$337.00K.
| Period end | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$180.00K 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | -$10.00K 10-Q · filed 2026-05-04 | |||
| 2025-12-31 | $254.00K 10-K · filed 2026-03-03 | |||
| 2025-09-30 | $689.00K 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | $305.00K 10-Q · filed 2026-08-05 | |||
| 2025-03-31 | $66.00K 10-Q · filed 2026-05-04 | |||
| 2024-12-31 | -$478.00K 10-K · filed 2026-03-03 | |||
| 2024-09-30 | -$262.00K 10-Q · filed 2025-11-05 | |||
| 2024-06-30 | -$174.00K 10-Q · filed 2025-08-05 | |||
| 2024-03-31 | -$130.00K 10-Q · filed 2025-05-07 | |||
| 2023-12-31 | -$90.00K 10-K · filed 2026-03-03 | |||
| 2023-09-30 | -$269.00K 10-Q · filed 2024-11-06 | |||
| 2023-06-30 | -$131.00K 10-Q · filed 2024-07-31 | |||
| 2023-03-31 | -$79.00K 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | -$337.00K 10-K · filed 2025-03-04 | |||
| 2022-09-30 | -$368.00K 10-Q · filed 2023-11-07 | |||
| 2022-06-30 | -$165.00K 10-Q · filed 2023-08-02 | |||
| 2022-03-31 | -$103.00K 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | $0.00 10-K · filed 2023-03-08 | |||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-08 | |||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-02 | |||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |